Cytomegalovirus Infections Market

Market Overview:

The 7 major cytomegalovirus infections markets are expected to exhibit a CAGR of 4.32% during 2024-2034.

The cytomegalovirus infections market has been comprehensively analyzed in IMARC's new report titled "Cytomegalovirus Infections Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cytomegalovirus infections refer to medical conditions that are caused by the cytomegalovirus, a member of the herpesvirus family. This disease can be spread through various routes, including direct contact with bodily fluids, such as saliva, urine, breast milk, blood, semen, vaginal secretions, etc. It can also be transmitted from mother to fetus during pregnancy or through organ transplantation. The infection can manifest in several ways, depending on the patient's immune status. Some common symptoms of the ailment include fever, fatigue, muscle aches, sore throat, swollen glands, general malaise, gastrointestinal issues, inflammation of the retina and liver, etc. Cytomegalovirus infections are typically diagnosed through a combination of clinical evaluation, laboratory testing, and medical history review. The healthcare provider may perform blood workups involving DNA polymerase chain reaction to detect the presence of viral genetic material in the blood and confirm a diagnosis among patients. In some cases, if the infection affects specific organs or tissues, a biopsy may be recommended to obtain a sample for laboratory analysis and rule out other causes of the underlying symptoms.

The increasing prevalence of exposure to infected fluids through activities like kissing, sexual contact, sharing utensils or drinks, etc., is primarily driving the cytomegalovirus infections market. In addition to this, the rising cases of weakened immune systems, in which the number and function of white blood cells are reduced, resulting in a decreased ability to control diseases, is also creating a positive outlook for the market. Moreover, the widespread adoption of antiviral drugs, including ganciclovir, valganciclovir, foscarnet, etc., since they work by inhibiting the replication of the virus, is further bolstering the market growth. Apart from this, the escalating application of intravenous immunoglobulin therapy that modulates the body's defense system, thereby potentially reducing inflammation and preventing or minimizing organ damage, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of hematopoietic stem cell transplants to treat the ailment, owing to their several associated benefits, such as effectively eliminating the viral load and improving overall patient outcomes, is expected to drive the cytomegalovirus infections market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the cytomegalovirus infections market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for cytomegalovirus infections and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cytomegalovirus infections market in any manner.

Recent Developments:

• In May 2024, Fortress Biotech, Inc. and its majority-owned subsidiary, Helocyte, Inc., reported that the first patient had been dosed in a multi-center, placebo-controlled, randomized Phase 2 study of Triplex, a CMV vaccination for patients undergoing liver transplantation.
• In December 2023, Takeda announced that LIVTENCITY (maribavir) had been approved by China's National Medical Products Administration (NMPA) for the treatment of adult individuals with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease that is resistant to treatment (with or without genotypic resistance) with valganciclovir, ganciclovir, cidofovir, or foscarnet.
• In June 2023, Merck announced that the U.S. FDA had approved a new indication for PREVYMIS (letermovir) for the prevention of cytomegalovirus disease in adult kidney transplant recipients at high-risk (donor CMV-seropositive/recipient CMV-seronegative [D+/R-]) after a priority review.

Key Highlights:

• Cytomegalovirus (CMV) is a prevalent virus with an estimated global seroprevalence of 83% of the population.
• CMV affects people of all ages; by the age of five, almost one-third of children in the United States are infected.
• Transmission rates for neonatal illnesses range between 30% and 50% when the initial infection occurred during pregnancy.
• Reactivation occurs in immunocompromised people and is associated with increased morbidity and death.
• Between 10% and 20% of people suffer sensorineural deafness or mental impairment.
• Sexual transmission is responsible for the increase in seroprevalence during adolescence and early adulthood.

Drugs:

PREVYMIS is a prescription medication that prevents viral replication by targeting the CMV DNA terminase complex. PREVYMIS is now authorized for the prevention of CMV infections in high-risk adult kidney transplant recipients (donor CMV-seropositive/recipient CMV-seronegative [D+/R-]).

Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb that targets human cytomegalovirus (hCMV). Fiztasovimab has a neutralizing effect via binding to the antigenic domain 1 of glycoprotein B on the hCMV envelope. This therapeutic candidate prevents hCMV transfer between cells.

mRNA-1647 is a vaccine that contains six mRNAs that encode for two proteins found on the surface of CMV: five mRNAs encoding the subunits that make up the membrane-bound pentamer complex and one mRNA coding the full-length membrane-bound glycoprotein B (gB). Both the pentamer and gB are required for CMV to infect barrier epithelial surfaces and gain entry into the body, which is the first stage of CMV infection. mRNA-1647 is intended to elicit an immune response against both the pentamer and gB, hence preventing CMV infection.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the cytomegalovirus infections market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the cytomegalovirus infections market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cytomegalovirus infections marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the cytomegalovirus infections market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the cytomegalovirus infections market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the cytomegalovirus infections market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of cytomegalovirus infections across the seven major markets?
• What is the number of prevalent cases (2018-2034) of cytomegalovirus infections by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of cytomegalovirus infections by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with cytomegalovirus infections across the seven major markets?
• What is the size of the cytomegalovirus infections patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of cytomegalovirus infections?
• What will be the growth rate of patients across the seven major markets?
   

Cytomegalovirus Infections: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for cytomegalovirus infections drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cytomegalovirus infections market?
• What are the key regulatory events related to the cytomegalovirus infections market?
• What is the structure of clinical trial landscape by status related to the cytomegalovirus infections market?
• What is the structure of clinical trial landscape by phase related to the cytomegalovirus infections market?
• What is the structure of clinical trial landscape by route of administration related to the cytomegalovirus infections market?